We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is changing its definition of face-to-face meetings to clarify that they include both in-person meetings and virtual meetings on audio- and video-enabled platforms. But at the moment it won’t be holding in-person meetings. Read More
AbbVie has filed a complaint against several generics producers — including Teva Pharmaceuticals and Novartis’ Sandoz unit — alleging the companies infringed on patents for its endometriosis drug Orilissa (elagolix) by planning to make generic alternatives. Read More
An FDA advisory committee voted 13-0 yesterday in favor of the agency’s long-term strategy for its Knowledge-Aided Assessment and Structured Application (KASA) program, including expanding it from just generic drugs to new drugs and biologics assessments over the next five years. Read More
The FDA handed Lupin a warning letter citing the company’s failure to correct cross-contamination issues noted in an inspection of its manufacturing plant in Palghar, India, earlier this year. Read More
Two gene replacement therapies to combat hemophilia are worth multimillion dollar price tags because they would eliminate the need for ongoing treatment with high-priced anticoagulant drugs, says the Institute for Clinical and Economic Review (ICER). Read More
An FDA advisory committee voted 9-0 yesterday in favor of the agency’s proposal to create an as-yet undefined rating system to incentivize drug manufacturers to adopt more mature quality management practices. Read More
AbbVie is seeking EMA marketing authorization for epcoritamab for treating patients with relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Read More